Loading...

PE anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_PE_040912
C57BL/6 mouse bone marrow cells were stained with Ly-6G/Ly-6C (clone RB6-8C5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram). Data shown was gated on myeloid cell population.
  • RB6-8C5_PE_040912
    C57BL/6 mouse bone marrow cells were stained with Ly-6G/Ly-6C (clone RB6-8C5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram). Data shown was gated on myeloid cell population.
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108407 50 µg $56
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108408 200 µg $183
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  2. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  3. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  4. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  5. Ostapoff K, et al. 2014. Cancer Res. 74:4966. PubMed
  6. Drobek A, et al. 2015. J Immunol. 195: 3416 - 3426. PubMed
  7. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  8. Baryawno N et al. 2019. Cell. 177(7):1915-1932 . PubMed
  9. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  10. Jackson A, et al. 2014. J Leukoc Biol. 92:609. PubMed
  11. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  12. Voronov E, et al. 2010. Int Immunol. 1.086805556. PubMed
  13. Matsushita Y, et al. 2021. J Bone Miner Res. 36:1145. PubMed
  14. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  15. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  16. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  17. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  18. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  19. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
  20. Lee Y, et al. 2017. PLoS One.. 10.1371/journal.pone.0183028. PubMed
  21. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  22. Shen H, et al. 2015. Infect Immun . 83: 2694 - 2704. PubMed
  23. Feng M, et al. 2014. Int Immunopharmacol. 19:267. PubMed
  24. Liu X, et al. 2013. Diabetes. 62:4228. PubMed
  25. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  26. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  27. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  28. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  29. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  30. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  31. Ohtsuki T, et al. 2016. J Virol. 90: 300 - 307. PubMed
  32. Peng J, et al. 2016. Nat Commun. 7:12029. PubMed
  33. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  34. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  35. Dey A et al. 2019. The EMBO journal. 38(7) pii: e100293. PubMed
  36. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  37. Kan C, et al. 2022. Bone Res. 10:62. PubMed
  38. Balachandran Y, et al. 2022. J Innate Immun. :1. PubMed
  39. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  40. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  41. Liu YY, et al. 2020. Chin Med J (Engl). 133:1688. PubMed
  42. Crnej A, et al. 2015. Invest Ophthalmol Vis Sci . 56:185. PubMed
  43. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  44. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  45. Li J, et al. 2019. JCI Insight. 5. PubMed
  46. Casey S, et al. 2011. Mol Endocrinol. 25:933. PubMed
  47. Keshavarz M, et al. 2020. Virol J. 17:64. PubMed
  48. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  49. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  50. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  51. Curtis MW, et al. 2018. Infect Immun. 86:e00186. PubMed
  52. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  53. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  54. Stumpfova M, et al. 2010. Cancer Res . 70:2962. PubMed
  55. Dang Y, et al. 2021. J Cancer. 12:7158. PubMed
  56. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  57. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  58. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  59. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  60. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  61. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  62. Suresh MV, et al. 2019. JCI Insight. 4:e133103. PubMed
  63. Yang M, et al. 2021. Cancer Immunol Immunother. 70:2467. PubMed
  64. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  65. Lira R, et al. 2016. PLoS One. 11: 0157475. PubMed
  66. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  67. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  68. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  69. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  70. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  71. Yan W, et al. 2021. Front Med (Lausanne). 8:752223. PubMed
  72. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  73. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  74. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  75. Wang Q, et al. 2018. Int J Biol Sci. 14:147. PubMed
  76. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  77. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  78. Pashover-Schallinger E, et al. 2012. FASEB J. 26:3891. PubMed
  79. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  80. Akk A, et al. 2019. Mol Immunol. 114:629. PubMed
  81. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  82. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  83. Patankar Y, et al. 2015. Am J Physiol Lung Cell Mol Physiol. 309: L902 - L913. PubMed
  84. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  85. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  86. Chen Y, et al. 2022. Life Sci. 306:120826. PubMed
  87. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  88. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  89. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  90. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  91. Ostapoff K, et al. 2013. Mol Cancer Ther. 12:1190. PubMed
  92. Mosa A, et al. 2009. Infect Immun. 77:2908. PubMed
  93. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  94. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  95. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  96. Koide S, et al. 2022. iScience. 25:103603. PubMed
  97. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  98. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  99. Rashid O, et al. 2013. Surgery. 153:771. PubMed
  100. Weckbach LT, et al. 2019. J Exp Med. 216:350. PubMed
  101. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  102. Filina J, et al. 2014. Cell Signal. 26:2138. PubMed
  103. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  104. Hsia HC, et al. 2017. J Leukoc Biol. 101:1053. PubMed
  105. Jordan PM, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  106. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  107. Darlyuk-Saadon I, et al. 2021. FEBS J. 288:3978. PubMed
  108. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  109. Chen J, et al. 2021. Oncol Lett. 21:409. PubMed
  110. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  111. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  112. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  113. Beyerle A, et al. 2011. J Control Release. 151:51. PubMed
  114. Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed
  115. Zhang M, et al. 2019. Autophagy. 1.423611111. PubMed
  116. Franklin R, et al. 2022. Nat Commun. 13:2350. PubMed
  117. Hegde V, et al. 2015. J Immunol. 194:5211. PubMed
  118. Rowe R, et al. 2016. J Exp Med. 213: 1497 - 1512. PubMed
  119. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  120. Guarnerio J, et al. 2018. Nat Commun. 9:66. PubMed
  121. Moriyasu T, et al. 2018. PLoS Negl Trop Dis. 12:e0006197. PubMed
  122. Terlizzi M, et al. 2021. Cell Physiol Biochem. 55:539. PubMed
  123. Xie Y, et al. 2020. Endocrinology. 161:00:00. PubMed
  124. Ramos-Sevillano E, et al. 2016. PLoS One. 12: 1005500. PubMed
  125. Weimershaus M, et al. 2012. J Immunol. 188:1789. PubMed
RRID
AB_313372 (BioLegend Cat. No. 108407)
AB_313373 (BioLegend Cat. No. 108408)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Go To Top Version: 2    Revision Date: 12/09/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account